Dinaciclib synergizes with BH3 mimetics targeting BCL‐2 and BCL‐XL in multiple myeloma cell lines partially dependent on MCL‐1 and in plasma cells from patients

Dinaciclib synergizes with BH3 mimetics targeting BCL‐2 and BCL‐XL in multiple myeloma cell lines partially dependent on MCL‐1 and in plasma cells from patients

A better understanding of multiple myeloma (MM) biology has led to the development of novel therapies. However, MM is still an incurable disease and new pharmacological strategies are needed. Dinaciclib, a multiple cyclin‐dependent kinase (CDK) inhibitor, which inhibits CDK1, 2, 5 and 9, displays si...

Full description

Bibliographic Details
Main Authors: Manuel Beltrán‐Visiedo, Nelia Jiménez‐Alduán, Rosana Díez, Marta Cuenca, Andrea Benedi, Alfonso Serrano‐Del Valle, Gemma Azaceta, Luis Palomera, Victor Peperzak, Alberto Anel, Javier Naval, Isabel Marzo
Format: Article
Language:English
Published: Wiley 2023-12-01
Series:Molecular Oncology
Subjects:
BCL‐2 proteins
BH3 mimetics
CDK inhibitors
cell death
multiple myeloma
Online Access:https://doi.org/10.1002/1878-0261.13522

Internet

https://doi.org/10.1002/1878-0261.13522

Similar Items